TitleBCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy.
Publication TypeJournal Article
Year of Publication2017
AuthorsCurran, KM, Schaffer, PA, Frank, CB, Lana, SE, Hamil, LE, Burton, JH, Labadie, J, Ehrhart, EJ, Avery, PR
JournalVet Comp Oncol
Date Published2017 Dec
KeywordsAnimals, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Cyclophosphamide, Dog Diseases, Dogs, Doxorubicin, Female, Lymph Nodes, Lymphoma, Large B-Cell, Diffuse, Male, Prednisone, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-myc, Treatment Outcome, Vincristine

Diffuse large B-cell lymphoma (DLBCL) is the most common haematopoietic malignancy in dogs. Recently, MYC and BCL2 expression levels determined with immunohistochemistry (IHC) were found to be prognostic in people with DLBCL. We hypothesized that canine DLBCL can be similarly subdivided into prognostic subtypes based on expression of MYC and BCL2. Cases of canine DLBCL treated with CHOP chemotherapy were retrospectively collected and 43 dogs had available histologic tissue and complete clinical follow-up. Median values of percent immunoreactive versus immunonegative cells were used to determine positive or negative expression status. Completion of CHOP was significantly associated with a positive outcome. Compared with human patients, our canine DLBCL patients had high IHC expression of both MYC and BCL2, and relative expression levels of one or both markers were not associated with clinical outcome.

Alternate JournalVet Comp Oncol
PubMed ID27514648